ArticleJHEP reports : innovation in hepatology2026
A subset of hepatic fibroblasts marked by Gli1 expression generates portal fibrosis and promotes ductular reaction.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The hepatic portal area in homeostasis and disease.Clinical and molecular hepatology · 2026Article
- Clec3b⁺ fibroblasts are the primary effectors of portal fibrosis following activation via a KLF4/periostin axis.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsGli1+ cells were previously described as myofibroblast precursors. We aimed to delineate the identity of Gli1+ cells and their contribution to wound healing in liver.
methodsGli1+ cells were analyzed in normal mouse liver by single-cell RNA sequencing (n = 3). Genetic cell fate tracing and depletion of Gli1+ cells were achieved in male mice, undergoing cholestatic injury induced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) or bile duct ligation (BDL), and metabolic dysfunction-associated steatohepatitis (MASH). Gli1 expression was examined by fluorescence in-situ hybridization in human liver (n = 16). Cell interactions were assessed using organoids.
resultsIn normal liver, Gli1 demarcated a periductal subpopulation (11.8%) of portal fibroblasts, which transcriptome pertains to extracellular matrix and structure organization. In liver injury, Gli1+ fibroblasts accumulated with fibrosis as multilayers around bile ducts and discontinuously along the inner border of the ductular reaction, predominantly in biliary models and less markedly in MASH. In humans, periductal Gli1+ cells were present in normal liver and accumulated in primary sclerosing cholangitis and, to a lesser extent, in MASH, notably alongside the ductular reaction in late-stage diseases. Co-culture of cholangiocyte organoids with Gli1+ fibroblasts showed bidirectional interactions fostering proliferation of both cell types. Genetic depletion of Gli1+ cells (n ≥4/group) caused a marked reduction of fibrosis, assessed by Sirius Red area, in DDC-fed and BDL mice after 1 week (p <0.01) and of ductular reaction, assessed by cytokeratin-19+ cell count in DDC (p <0.01), although cholestatic injury persisted or even increased.
conclusionsGli1 demarcates a subpopulation of fibroblasts that play a key role in the wound healing process combining portal fibrosis and ductular reaction notably in biliary diseases. IMPACT AND IMPLICATIONS: The heterogeneity and the functions of hepatic fibroblasts in liver fibrosis remain poorly defined. Gli1+ fibroblasts are a transcriptionally distinct subset of hepatic fibroblasts, mainly located around bile ducts. Gli1+ fibroblasts develop bidirectional interactions with cholangiocytes, underlying portal fibrosis and ductular reaction formation, as they typically occur in biliary diseases. The therapeutic targeting of Gli1+ hepatic fibroblasts is of potential interest in biliary diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.